PMID- 11586103
OWN - NLM
STAT- MEDLINE
DCOM- 20011101
LR  - 20190906
IS  - 0277-3732 (Print)
IS  - 0277-3732 (Linking)
VI  - 24
IP  - 5
DP  - 2001 Oct
TI  - Overexpression of the HER-2/neu oncogene in pancreatic adenocarcinoma.
PG  - 496-9
AB  - Novel systemic treatments are needed in pancreatic cancer. The authors sought to 
      establish the frequency of overexpression of the HER-2/neu oncogene in patients 
      with pancreatic adenocarcinoma to determine the potential role of trastuzumab 
      (Herceptin) as a therapeutic agent in this disease. Tumor specimens from patients 
      with pancreatic adenocarcinoma were analyzed by staining for p185HER2 protein 
      using the DAKO immunohistochemical assay. Patients with and without HER-2/neu 
      overexpression by immunohistochemistry were compared with respect to clinical and 
      pathologic characteristics. HER-2/neu gene amplification was also evaluated by 
      fluorescence in situ hybridization (FISH). Thirty-two of 154 patients (21%) had 
      pancreatic adenocarcinoma that demonstrated HER-2/neu overexpression by 
      immunohistochemistry. At initial diagnosis, 16% of resectable cancers, 17% of 
      locally advanced cancers, and 26% of metastatic cancers were determined to have 
      HER-2/neu overexpression. Three of 11 (27%) patients with HER-2/neu 
      overexpression by immunohistochemistry had gene amplification by FISH. HER-2/neu 
      overexpression occurs in a subset of pancreatic cancer. Evaluation of the 
      efficacy of trastuzumab for patients with pancreatic cancer who overexpress 
      HER-2/neu appears indicated.
FAU - Safran, H
AU  - Safran H
AD  - Brown University Oncology Group, Providence, Rhode Island, USA.
FAU - Steinhoff, M
AU  - Steinhoff M
FAU - Mangray, S
AU  - Mangray S
FAU - Rathore, R
AU  - Rathore R
FAU - King, T C
AU  - King TC
FAU - Chai, L
AU  - Chai L
FAU - Berzein, K
AU  - Berzein K
FAU - Moore, T
AU  - Moore T
FAU - Iannitti, D
AU  - Iannitti D
FAU - Reiss, P
AU  - Reiss P
FAU - Pasquariello, T
AU  - Pasquariello T
FAU - Akerman, P
AU  - Akerman P
FAU - Quirk, D
AU  - Quirk D
FAU - Mass, R
AU  - Mass R
FAU - Goldstein, L
AU  - Goldstein L
FAU - Tantravahi, U
AU  - Tantravahi U
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Am J Clin Oncol
JT  - American journal of clinical oncology
JID - 8207754
RN  - 0 (Antibodies, Monoclonal)
RN  - 0 (Antibodies, Monoclonal, Humanized)
RN  - 0 (Antineoplastic Agents)
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
RN  - P188ANX8CK (Trastuzumab)
SB  - IM
EIN - Am J Clin Oncol 2002 Apr;25(2):181
MH  - Aged
MH  - Antibodies, Monoclonal/therapeutic use
MH  - Antibodies, Monoclonal, Humanized
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Pancreatic Ductal/drug therapy/genetics/*metabolism/pathology
MH  - Female
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence
MH  - Male
MH  - Middle Aged
MH  - Pancreatic Neoplasms/drug therapy/genetics/*metabolism/pathology
MH  - Receptor, ErbB-2/genetics/*metabolism
MH  - Trastuzumab
EDAT- 2001/10/05 10:00
MHDA- 2001/11/03 10:01
CRDT- 2001/10/05 10:00
PHST- 2001/10/05 10:00 [pubmed]
PHST- 2001/11/03 10:01 [medline]
PHST- 2001/10/05 10:00 [entrez]
AID - 10.1097/00000421-200110000-00016 [doi]
PST - ppublish
SO  - Am J Clin Oncol. 2001 Oct;24(5):496-9. doi: 10.1097/00000421-200110000-00016.